Meeting Venue: Room 331, Level 3, Suntec Singapore

 

Time

Programme

10:00 – 11:20

HBV Cure Overview

Chair and Moderator : Seng Gee Lim (Singapore)

10:00 – 10:10

Opening Lecture: How to Eradicate HBV?

Geoffrey Dusheiko, UK

10:10 – 10:20

State of the Action: HBV Cure Strategy from HBV Foundation

Robert Gish, HBV Foundation

10:20 – 10:40

International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) Progress Report 2019           

Peter Revill, Australia

10:40 – 10:55

HBV Forum: Achievements to Date

Veronica Miller, USA

10:55 – 11:05

Insights for HBV Cure from HIV Cure Strategies

Jonathan Karn, USA

11:05– 11:20

Discussion Forum led by the Moderator

11:20 – 12:10

Models for HBV Infection

Chair and Moderator : Atefeh Khakpoor (Singapore)

11:20 – 11:35

Novel In-Vitro Models : An Overview

Peter Revill, Australia

11:35 – 11:50

Humanised Mouse Models: State of the Art

Qingfeng Chen, Singapore

11:50 – 12:10

Discussion Forum led by the Moderator

12:10 – 13:00

Lunch

13:00 – 14:30

Clinical & Translational Forum

Chair and Moderator: Peter Revill (Australia)

13:00 – 13:15

Insights into Host Genes in HBV Clearance 

Martin Hibberd, Singapore

13:15 – 13:30

HBV Viral Integration : Implications for a HBV Cure

Stephan Urban, Germany

Invited Oral & Free Paper Presentations

13:30 – 13:45

Development of Novel Markers of Treatment Response

Gavin Cloherty, Abbott Diagnostics

13:45 – 13:55

Understanding IFN Subtype: Harnessing the Power of IFN for HBV Cure

Zhenghong Yuan, China

13:55 – 14:05

HBV Surface Antigen Large And Middle Isoform Composition Do Not Correlate To Disease Stage

Gavin Cloherty, Abbott Laboratories

14:05 – 14:15

Free Paper

14:15 – 14:30

Discussion Forum led by the Moderator

14:30 – 16:25

Viral Transcription

Chair and Moderator: Stephen Locarnini (Australia)

14:30 – 14:45

cccDNA Update: Where Are We in 2019?

Haitao Guo, USA

14:45 – 15:00

State of the Art: CRISPR-CAS9 in Human Cells

Tan Meng How, Singapore

15:00 – 15:30

Debate: HBV cccDNA Management

·       It is better to eliminate cccDNA: Massimo Levrero, France

·       It is better to silence cccDNA: Haitao Guo, USA

Invited Oral & Free Paper Presentations

15:30 – 15:40

Using a modified HBV genome and insertional chromatin immunoprecipitation to screen for cccDNA-associated nuclear factors

Nur Khairiah Mohd-Ismail, Singapore

15:40 – 15:50

A first-in-class orally available HBV cccDNA destabilizer ccc_R08 achieved sustainable HBsAg and cccDNA reduction in the HBVcircle mouse model

Lu Gao, Roche

15:50 – 16:00

Thiazolides in the treatment of chronic HBV: Can it be a cure

Jean-François Rossignol, Romark, L.C

16:00 – 16:10

Free Paper

16:10 – 16:25

Discussion Forum led by the Moderator

16:25 – 16:40

Tea Break

16:40 – 18:00

Capsid Inhibition

Chair and Moderator: Jorg Peterson (Germany)

16:40 – 16:55

Mechanism and Efficacy of Capsid Inhibitors

Stephen Locarnini, Australia

16:55 – 17:10

Biology of HBV Core Phosphorylation and Targets

Pei-Jer Chen, Taiwan

Invited Oral & Free Paper Presentations

17:10 – 17:20

RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients 

Man-Fung Yuen, Hong Kong

17:20 – 17:30

Janssen Pharmaceutica

17:30 – 17:40

Proteome and Phosphosproteome profiling Of Hepatitis B Virus (HBV)-Infected Cells

Lim Zijie, Singapore

17:40 – 18:00

Discussion Forum led by the Moderator

End of Day 1

Please, note that the programme is subject to change, and will be updated continuously up to the conference.

Meeting Venue: Room 331, Level 3, Suntec Singapore

 

Time

Programme

09:00 – 09:30

Special Lecture

Chair and Moderator: Gary Levy (Canada)

09:00 – 09:15

Entry Inhibitor Alone or with Antiviral Therapy to Treat HBV

Stephan Urban, Germany

09:15 – 09:30

Discussion Forum led by the Moderator

09:30 – 10:15

Debate: Can HBV be Cured by Antiviral Therapy Alone?

Chair and Moderator: Stephen Locarnini (Australia)

09:30 – 10:00

·       Yes:     Fabien Zoulim, France

·       No:      Antonio Bertoletti, Singapore

10:00 – 10:15

Discussion Forum led by the Moderator

10:15 – 11:30

Immunology Forum Part 1

Chair and Moderator: Jonathan Karn (USA)

10:15 – 10:30

Immune Correlates of HBsAg Clearance

Robert Thimme, Germany

10:30 – 10:45

The Role of Innnate Immunity in Functional Cure

Fabien Zoulim, France

Invited Oral & Free Paper Presentations

10:45 – 10:55

Gilead Sciences

10:55 – 11:05

Update on Inarigivir, a Novel RIG-I agonist to Stimulate Innate Immunity and Promote Functional Cure in Chronic HBV

Nezam H. Afdhal, Spring Bank Pharmaceuticals

11:05 – 11:15

Free paper

11:15 – 11:30

Discussion Forum led by the Moderator

11:30 – 11:45

Tea Break

11:45 – 12:50

Immunology Forum Part 2

Chair and Moderator: Fabien Zoulim (France)

11:45 – 12:00

Overview of Adaptive Immune Therapies for CHB

Robert Thimme, Germany

12:00 – 12:15

Car-T therapy: Principles and Applicability

Jonathan Karn, USA

Invited Oral & Free Paper Presentations

12:15 – 12:25

HDV co-infection modifies the immunoproteasome profile of HBV infected hepatocytes leading to increased CD8 T-cell recognition: Implication for immunotherapy

Christine, Y.L. Tham, Singapore

12:25 – 12:35

Comparative Characterization of B cells Specific for HBV Nucleocapside and Envelope Proteins in Patients with Chronic Hepatitis B

Loghman Salimzadeh, Singapore

12:35 – 12:50

Discussion Forum led by the Moderator

12:50 – 13:30

Lunch

13:30 – 14:40

Reducing Viral Antigens

Chair and Moderator: Massimo Levrero (Italy)

13:30 – 13:45

Cytokine – Chemokine Profiling in Patients with S loss

John Connolly, Singapore

13:45– 14:00:

Immune Recovery after Reduction in Viral proteins

Sriram Narayanan, Singapore

Invited Oral & Free Paper Presentations

14:00 – 14:10

To be confirmed

Bruce Given, Arrowhead Pharmaceuticals

14:10 – 14:20

Targeting HBV Using Immune Mobilising Monoclonal TCRS Against Virus (Immtav®)

Praveen Kumar Singh, UK

14:20 – 14:40

Discussion Forum led by the Moderator

14:40 – 15:25

Combination Therapy Symposium

Chair and Moderator: Seng Gee Lim (Singapore)

14:40 – 14:55

Studies of Combination Antiviral Therapy – what works and what doesn’t

Jorg Peterson, Germany

14:55 – 15:05

To be confirmed

Edward Chau, Singapore

15:05 – 15:15

Roche: CHB Combination Therapies

Cynthia Wat, Roche

15:15 – 15:25

Establishing functional cure of chronic HBV infection with nucleic acid polymers: Final results of the REP 401 study

Andrew Vaillant, Replicor Inc

15:25 – 17:30

Combination Therapy Forum

Moderator: Edward Gane (New Zealand)

15:25 – 17:30

Robert Gish (USA), Stephan Urban (Germany), Robert Thimme (Germany), Nezam H. Afdhal (Spring Bank Pharmaceuticals), Andrew Vaillant (Replicor Inc), Cynthia Wat (Roche), Oliver Lenz (Janssen Pharmaceutica), Bruce Given (Arrowhead Pharmaceuticals)

17:30

Closing remarks from Chairman

 

Please, note that the programme is subject to change, and will be updated continuously up to the conference.